Drug Research

Teva Pharmaceutical Industries Ltd and Celltrion Healthcare announce that the companies have entered into an exclusive partnership to commercialize two of Celltrion’s mAb biosimilar candidates in the U.S. and Canada. CT-P10 is a proposed mAb biosimilar to Rituxan® (rituximab)....

Daiichi Sankyo Company, Limited has entered into a strategic collaboration with AgonOx, Inc., a privately held biotechnology company, to develop an undisclosed immuno-oncology target.   Under terms of the agreement, Daiichi Sankyo and AgonOx will collaborate...

Recursion Pharmaceuticals announced its $12.9 million Series A round of funding, led by leading deep technology investor Lux Capital, with participation from Obvious Ventures, Epic Ventures, Data Collective, AME Cloud Ventures, Wild Basin Investments, and several prominent angel investors....

Bayer and DelSiTech Ltd , a Finnish drug delivery technology and drug development company, have signed a Collaboration and Technology Licence Agreement for the worldwide application of DelSiTech’s Silica Matrix drug delivery platform to a number of Bayer’s compounds...

Amgen and Arrowhead Pharmaceuticals Inc announced two license and collaboration agreements to develop and commercialize RNA interference (RNAi) therapies for cardiovascular disease. These are the first programs to utilize Arrowhead's proprietary subcutaneous RNAi delivery platform. RNAi...

Boehringer Ingelheim and ViraTherapeutics announced a long term collaboration to jointly develop a next generation oncolytic virus therapy platform and to investigate Vira Therapeutic’s lead candidate VSV-GP (Vesicular Stomatitis Virus (VSV) glycoprotein (GP)) alone and in combination with other...

Catalent Pharma Solutions (Booth 3J16), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products announced a full agenda for the upcoming CPhI Worldwide Conference and Exhibition, to be held at...